A team of international researchers, including Hector Gomez from Purdue University, have paved the way for earlier detection of prostate cancer recurrence after radiation therapy.
With a new patent-pending technique and algorithm, these scientists have aimed to give patients and healthcare providers a head start in managing and potentially treating the return of prostate cancer, which can often take years to detect with current practices.
Leveraging Data to Forecast Cancer Recurrence
Radiation has been widely utilized to treat prostate cancer tumors, benefiting patients across various age and risk categories.
Despite its effectiveness, a notable percentage of patients, between 20% to 30%, experience a recurrence of the cancer, typically after a five-year period following therapy.
The recurrence is generally identified through a gradual rise in prostate-specific antigen (PSA) levels in the blood.
Hector Gomez and his colleagues, based in Italy and Spain, have forged a new path with a method that uses patient-specific forecasts of PSA dynamics to anticipate cancer recurrence.
Their groundbreaking research has found its place in iScience, a peer-reviewed open access journal.
How the Predictive Algorithm Works
The algorithm is deeply rooted in a model that is specific to individual patients and utilizes their periodic PSA measurements, which are a standard part of monitoring for prostate cancer post-radiation therapy.
Gomez explains, “The PSA data is used in conjunction with the model to obtain patient-specific parameters that determine the PSA dynamics and serve as classifiers for recurrence.”
Beyond identifying recurrence, the model also aids in establishing personalized PSA monitoring strategies, helping physicians determine optimal times to investigate tumor recurrences and thereby enhancing the possibility of effective secondary treatment.
Proving the Method with Retrospective Data
The research team put their method to the test with retrospective data from 166 patients.
When compared with traditional medical practice, their model demonstrated its efficacy by predicting recurrence a median of 14.8 months earlier than current methods.
“This early detection is vital. It does not only flag recurrence but also provides physicians with a timely window to consider and deploy secondary treatments, maximizing the potential for targeting recurring tumors,” says Gomez.
Looking Forward to Expanded Applications
The current model has its limitations – it’s applicable only to patients who undergo radiation without additional treatments like hormone therapy. Gomez indicates that future developments are in the pipeline.
“We plan to extend the method to make it applicable also to patients who receive radiation and hormone therapy simultaneously,” he says.
The innovative approach developed by Gomez and his colleagues marks a significant advancement in the proactive management of prostate cancer post-radiation.
While further development is anticipated, this method symbolizes a meaningful stride toward enhancing the precision and timeliness of recurrence detection, thus opening up avenues for timely intervention and treatment.
This can ultimately lead to improved patient outcomes and establishes a foundation for further innovations in cancer recurrence prediction and management.
If you care about cancer, please read studies about a new method to treat cancer effectively, and this low-dose, four-drug combo may block cancer spread.
For more information about cancer prevention, please see recent studies about nutrient in fish that can be a poison for cancer, and results showing this daily vitamin is critical to cancer prevention.
The research findings can be found in iScience.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
